Wockhardt Limited (WOCKPHARMA.BO)
INR 1264.45
(4.26%)
INR 1264.45
(4.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -670 Million INR | 61.05% |
| 2022 | -1.72 Billion INR | -654.84% |
| 2021 | 310 Million INR | 109.91% |
| 2020 | -3.12 Billion INR | -134.01% |
| 2019 | -1.33 Billion INR | 30.11% |
| 2018 | -1.91 Billion INR | 6.66% |
| 2017 | -2.04 Billion INR | -67.03% |
| 2016 | -1.22 Billion INR | -133.39% |
| 2015 | 3.67 Billion INR | -38.83% |
| 2014 | 6 Billion INR | -34.95% |
| 2013 | 9.23 Billion INR | -52.95% |
| 2012 | 19.63 Billion INR | 55.94% |
| 2011 | 12.59 Billion INR | 54.41% |
| 2010 | 8.15 Billion INR | 15.73% |
| 2009 | 7.04 Billion INR | -1.94% |
| 2008 | 7.18 Billion INR | 18.46% |
| 2007 | 6.06 Billion INR | 69.81% |
| 2006 | 3.57 Billion INR | 11.44% |
| 2005 | 3.2 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 380 Million INR | 200.0% |
| 2023 Q4 | -380 Million INR | -280.0% |
| 2023 FY | -670 Million INR | 61.05% |
| 2023 Q1 | -510 Million INR | -24.39% |
| 2023 Q2 | 170 Million INR | 133.33% |
| 2023 Q3 | -100 Million INR | -158.82% |
| 2022 FY | -1.72 Billion INR | -654.84% |
| 2022 Q1 | -800 Million INR | 13.04% |
| 2022 Q2 | -220 Million INR | 72.5% |
| 2022 Q3 | -70 Million INR | 68.18% |
| 2022 Q4 | -410 Million INR | -485.71% |
| 2021 Q3 | 518.4 Million INR | 7.84% |
| 2021 FY | 310 Million INR | 109.91% |
| 2021 Q1 | 432 Million INR | 129.73% |
| 2021 Q2 | 480.7 Million INR | 11.27% |
| 2021 Q4 | -920 Million INR | -277.47% |
| 2020 Q4 | -1.45 Billion INR | -259.59% |
| 2020 FY | -3.12 Billion INR | -134.01% |
| 2020 Q3 | 910.4 Million INR | 476.04% |
| 2020 Q2 | -242.1 Million INR | 79.84% |
| 2020 Q1 | -1.2 Billion INR | 22.37% |
| 2019 Q3 | 541 Million INR | 235.76% |
| 2019 Q2 | -398.5 Million INR | 14.98% |
| 2019 FY | -1.33 Billion INR | 30.11% |
| 2019 Q4 | -1.54 Billion INR | -385.86% |
| 2019 Q1 | -468.7 Million INR | -584.19% |
| 2018 Q1 | -272.9 Million INR | 48.23% |
| 2018 FY | -1.91 Billion INR | 6.66% |
| 2018 Q4 | 96.8 Million INR | 116.99% |
| 2018 Q3 | -569.9 Million INR | -271.09% |
| 2018 Q2 | 333.1 Million INR | 222.06% |
| 2017 Q1 | -602.3 Million INR | 58.48% |
| 2017 FY | -2.04 Billion INR | -67.03% |
| 2017 Q4 | -527.1 Million INR | -215.09% |
| 2017 Q3 | 458 Million INR | 15.45% |
| 2017 Q2 | 396.7 Million INR | 165.86% |
| 2016 Q4 | -1.45 Billion INR | -884.06% |
| 2016 FY | -1.22 Billion INR | -133.39% |
| 2016 Q2 | 820.5 Million INR | 46.89% |
| 2016 Q1 | 558.6 Million INR | 20.28% |
| 2016 Q3 | -147.4 Million INR | -117.96% |
| 2015 Q3 | 797.5 Million INR | -43.04% |
| 2015 FY | 3.67 Billion INR | -38.83% |
| 2015 Q1 | 1.52 Billion INR | 226.65% |
| 2015 Q2 | 1.4 Billion INR | -8.01% |
| 2015 Q4 | 464.4 Million INR | -41.77% |
| 2014 Q1 | 401.6 Million INR | -63.12% |
| 2014 FY | 6 Billion INR | -34.95% |
| 2014 Q4 | 466 Million INR | -88.9% |
| 2014 Q3 | 4.19 Billion INR | 337.17% |
| 2014 Q2 | 960.5 Million INR | 139.17% |
| 2013 FY | 9.23 Billion INR | -52.95% |
| 2013 Q4 | 1.08 Billion INR | -62.81% |
| 2013 Q1 | 3.73 Billion INR | -20.35% |
| 2013 Q3 | 2.92 Billion INR | 96.99% |
| 2013 Q2 | 1.48 Billion INR | -60.25% |
| 2012 Q4 | 4.69 Billion INR | -7.58% |
| 2012 Q1 | 4.45 Billion INR | -15.29% |
| 2012 FY | 19.63 Billion INR | 55.94% |
| 2012 Q2 | 5.39 Billion INR | 21.32% |
| 2012 Q3 | 5.08 Billion INR | -5.92% |
| 2011 Q4 | 5.25 Billion INR | 67.44% |
| 2011 FY | 12.59 Billion INR | 54.41% |
| 2011 Q3 | 3.13 Billion INR | 0.0% |
| 2010 FY | 8.15 Billion INR | 15.73% |
| 2009 FY | 7.04 Billion INR | -1.94% |
| 2008 FY | 7.18 Billion INR | 18.46% |
| 2007 FY | 6.06 Billion INR | 69.81% |
| 2006 FY | 3.57 Billion INR | 11.44% |
| 2005 FY | 3.2 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 111.636% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 101.588% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 107.462% |
| Granules India Limited | 6.81 Billion INR | 109.829% |
| Indoco Remedies Limited | 1.29 Billion INR | 151.836% |
| Achyut Healthcare Limited | 4.43 Million INR | 15196.89% |
| Ajanta Pharma Limited | 19.67 Billion INR | 103.405% |
| Alkem Laboratories Limited | 19.46 Billion INR | 103.443% |
| Alpa Laboratories Limited | 184.49 Million INR | 463.15% |
| Brooks Laboratories Limited | 14.44 Million INR | 4739.889% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 139.01% |
| Bajaj HealthCare Limited | - INR | Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 154.427% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 100.989% |
| Eris Lifesciences Limited | 5.18 Billion INR | 112.93% |
| FDC Limited | 2.98 Billion INR | 122.436% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 110.304% |
| Gufic Biosciences Limited | 1.32 Billion INR | 150.379% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 115.156% |
| Ipca Laboratories Limited | 7.98 Billion INR | 108.395% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 231.856% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | -340.914% |
| Lasa Supergenerics Limited | -458 Million INR | -46.287% |
| Laurus Labs Limited | 3.94 Billion INR | 116.968% |
| Lupin Limited | 28.04 Billion INR | 102.389% |
| Mankind Pharma Limited | 21.51 Billion INR | 103.114% |
| Medicamen Biotech Limited | - INR | Infinity% |
| Medico Remedies Limited | 100.3 Million INR | 767.996% |
| Megasoft Limited | -121.1 Million INR | -453.243% |
| NATCO Pharma Limited | 25.96 Billion INR | 102.581% |
| Piramal Pharma Limited | 4.55 Billion INR | 114.703% |
| RPG Life Sciences Limited | 2.29 Billion INR | 129.228% |
| Sigachi Industries Limited | 1.47 Billion INR | 145.458% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 100.642% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 114.541% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 368.805% |
| Unichem Laboratories Limited | - INR | Infinity% |
| Wanbury Limited | 569.71 Million INR | 217.602% |
| Windlas Biotech Limited | 1.29 Billion INR | 151.583% |
| ZIM Laboratories Limited | 253.82 Million INR | 363.957% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 101.554% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 83.718% |
| Divi's Laboratories Limited | 33.08 Billion INR | 102.025% |
| Hester Biosciences Limited | 364.81 Million INR | 283.657% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 124.049% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 246.434% |
| Bal Pharma Limited | 233.9 Million INR | 386.436% |
| Strides Pharma Science Limited | 5.22 Billion INR | 112.821% |
| Venus Remedies Limited | 534.65 Million INR | 225.315% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 121.419% |
| Nectar Lifesciences Limited | 923.8 Million INR | 172.526% |
| Shilpa Medicare Limited | 1.36 Billion INR | 149.039% |
| Aarti Drugs Limited | 7.14 Billion INR | 109.372% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 141.959% |
| Suven Life Sciences Limited | -1.22 Billion INR | 45.343% |
| Ind-Swift Limited | 1.22 Billion INR | 154.651% |
| Valiant Laboratories Limited | - INR | Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 104.691% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 82.611% |
| Themis Medicare Limited | 392.58 Million INR | 270.662% |
| Hikal Limited | 32.11 Million INR | 2186.577% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 102.645% |
| Sequent Scientific Limited | - INR | Infinity% |
| Novartis India Limited | 626.5 Million INR | 206.943% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 112.912% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | 7488.049% |
| Neuland Laboratories Limited | 5.31 Billion INR | 112.599% |
| Morepen Laboratories Limited | 4.17 Billion INR | 116.052% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 422.038% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 2540.09% |